Electra Therapeutics targets $978M valuation in IPO

Drug developer Electra Therapeutics aims for a valuation of up to $977.6 million in its US initial public offering. The company is offering about 21.67 million shares to raise up to $346.7 million.

Xurve View
Insights:
FILE PHOTO: The Nasdaq logo is displayed on a screen at the Nasdaq Market site in New York City, U.S., April 17, 2026. REUTERS/Brendan McDermid//File Photo

Drug developer Electra Therapeutics is targeting a valuation of up to $977.6 million in its United States IPO, seeking to raise as much as $346.7 million. The offering extends a biotech listings rebound during a slower-than-usual fall IPO window. Electra plans to offer about 21.67 million shares priced between $14 and $16 apiece.